Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. – SYRS
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. (“Syros” or the “Company”) (NASDAQ: SYRS).
INVESTORS OF SYROS PHARMACEUTICALS STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SYROS SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.
After the market closed on November 12, 2024, Syros announced that “[o]n November 12, 2024, an event of default occurred under the Loan and Security Agreement dated February 12, 2020 . . . between Syros Pharmaceuticals, Inc. . . . and Oxford Finance LLC (the “Lender”), as a result of the failure of the Company’s SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome patients with RARA gene overexpression to meet its primary endpoint of complete response rate.”
On this news, the stock price of Syros was down more than 86% during intraday trading on November 13, 2024.
SYROS INVESTORS WITH FINANCIAL LOSSES ALSO CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE SYROS SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.
